Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.

Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, Disselhorst M, Klomp H, Hartemink K, Burgers S, Buikhuisen W, Baas P.

J Thorac Oncol. 2018 Oct;13(10):1569-1576. doi: 10.1016/j.jtho.2018.05.038. Epub 2018 Jun 14.

2.

Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.

Kwint M, Walraven I, Burgers S, Hartemink K, Klomp H, Knegjens J, Verheij M, Belderbos J.

Lung Cancer. 2017 Oct;112:134-139. doi: 10.1016/j.lungcan.2017.08.006. Epub 2017 Aug 12.

PMID:
29191586
3.

Peri- and postoperative management of stage I-III Non Small Cell Lung Cancer: Which quality of care indicators are evidence-based?

Numan RC, Berge MT, Burgers JA, Klomp HM, van Sandick JW, Baas P, Wouters MW.

Lung Cancer. 2016 Nov;101:129-136. doi: 10.1016/j.lungcan.2016.06.007. Epub 2016 Jun 14. Review.

PMID:
27794401
4.

Pre- and postoperative care for stage I-III NSCLC: Which quality of care indicators are evidence-based?

Numan RC, Berge MT, Burgers JA, Klomp HM, van Sandick JW, Baas P, Wouters MW.

Lung Cancer. 2016 Nov;101:120-128. doi: 10.1016/j.lungcan.2016.05.022. Epub 2016 Sep 22. Review.

PMID:
27794400
5.

Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib.

van Gool MH, Aukema TS, Sinaasappel M, Valdés Olmos RA, Klomp HM.

J Thorac Dis. 2016 Mar;8(3):E200-3. doi: 10.21037/jtd.2016.02.10.

6.

Management of large mediastinal masses: surgical and anesthesiological considerations.

Li WW, van Boven WJ, Annema JT, Eberl S, Klomp HM, de Mol BA.

J Thorac Dis. 2016 Mar;8(3):E175-84. doi: 10.21037/jtd.2016.02.55. Review.

7.

Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up.

Konings R, van Gool MH, Bard MP, Zwijnenburg A, Titulaer BM, Aukema TS, Valdés Olmos RA, Sikorska K, Klomp HM, Rijna H.

Ann Nucl Med. 2016 Jun;30(5):362-8. doi: 10.1007/s12149-016-1070-2. Epub 2016 Mar 10.

PMID:
26961089
8.

Real-time In Vivo Tissue Characterization with Diffuse Reflectance Spectroscopy during Transthoracic Lung Biopsy: A Clinical Feasibility Study.

Spliethoff JW, Prevoo W, Meier MA, de Jong J, Klomp HM, Evers DJ, Sterenborg HJ, Lucassen GW, Hendriks BH, Ruers TJ.

Clin Cancer Res. 2016 Jan 15;22(2):357-65. doi: 10.1158/1078-0432.CCR-15-0807. Epub 2015 Aug 31.

9.

Optimal surgical management of pulmonary metastases: VATS versus thoracotomy.

Numan RC, Baas P, Klomp HM, Wouters MW.

Respirology. 2016 Jan;21(1):188-90. doi: 10.1111/resp.12607. Epub 2015 Aug 9.

10.

Rebuttal From Dr Li et al.

Li WW, Burgers JA, Klomp HM, Hartemink KJ.

Chest. 2015 Dec;148(6):1380-1381. doi: 10.1378/chest.15-1197. No abstract available.

PMID:
26110719
11.

COUNTERPOINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? No.

Li WW, Burgers JA, Klomp HM, Hartemink KJ.

Chest. 2015 Dec;148(6):1375-1379. doi: 10.1378/chest.15-1196. No abstract available.

PMID:
26110487
12.

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.

Lankheet NA, Schaake EE, Burgers SA, van Pel R, Beijnen JH, Huitema AD, Klomp H; NEL Study Group.

Clin Lung Cancer. 2015 Jul;16(4):320-4. doi: 10.1016/j.cllc.2014.12.012. Epub 2014 Dec 31.

PMID:
25682545
13.

FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.

van Gool MH, Aukema TS, Hartemink KJ, Valdés Olmos RA, van Tinteren H, Klomp HM.

World J Radiol. 2014 Jul 28;6(7):392-8. doi: 10.4329/wjr.v6.i7.392. Review.

14.

(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.

van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers SA, van Tinteren H, Klomp HM.

Ann Surg Oncol. 2014 Sep;21(9):2831-7. doi: 10.1245/s10434-014-3791-6. Epub 2014 May 21.

PMID:
24845729
15.

eComment. Circulating tumour cells caused by surgical manipulation in patients with lung cancer. Is minimally invasive "no-touch" surgery the solution?

Li WW, Klomp HM, van Boven WJ, de Mol BA.

Interact Cardiovasc Thorac Surg. 2014 Jun;18(6):783. doi: 10.1093/icvts/ivu160. No abstract available.

PMID:
24842979
16.

Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.

van Gool MH, Aukema TS, Schaake EE, Rijna H, Valdés Olmos RA, van Pel R, Burgers SA, van Tinteren H, Klomp HM; NEL Study Group.

J Nucl Med. 2014 Jul;55(7):1081-6. doi: 10.2967/jnumed.113.130674. Epub 2014 May 8.

17.

Postmenopausal bleeding and corticosteroids.

Klomp HA, van der Linden PJ.

Gynecol Obstet Invest. 2013;76(4):260. doi: 10.1159/000351105. Epub 2013 May 28. No abstract available.

PMID:
23735996
18.

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus.

Blaauwgeers JL, Kappers I, Klomp HM, Belderbos JS, Dijksman LM, Smit EF, Postmus PE, Paul MA, Oosterhuis JW, Hartemink KJ, Vos CG, Burgers JA, Dahele M, Phernambucq EC, Witte BI, Thunnissen E.

Virchows Arch. 2013 May;462(5):547-56. doi: 10.1007/s00428-013-1404-6. Epub 2013 Apr 3.

PMID:
23549732
19.

Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.

Wicherts DA, van Coevorden F, Klomp HM, van Huizum MA, Kerst JM, Haas RL, van Boven HH, van der Hage JA.

World J Surg Oncol. 2013 Mar 8;11:59. doi: 10.1186/1477-7819-11-59.

20.

Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy.

Spliethoff JW, Evers DJ, Klomp HM, van Sandick JW, Wouters MW, Nachabe R, Lucassen GW, Hendriks BH, Wesseling J, Ruers TJ.

Lung Cancer. 2013 May;80(2):165-71. doi: 10.1016/j.lungcan.2013.01.016. Epub 2013 Feb 10.

PMID:
23402823
21.

A clinical audit in a multidisciplinary care path for thoracic surgery: an instrument for continuous quality improvement.

Numan RC, Klomp HM, Li W, Buitelaar DR, Burgers JA, Van Sandick JW, Wouters MW.

Lung Cancer. 2012 Dec;78(3):270-5. doi: 10.1016/j.lungcan.2012.08.006. Epub 2012 Sep 20.

PMID:
22999081
22.

Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.

Schaake EE, Kappers I, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers JA, van Tinteren H, Klomp HM.

J Clin Oncol. 2012 Aug 1;30(22):2731-8. doi: 10.1200/JCO.2011.39.4882. Epub 2012 Jul 2.

PMID:
22753915
23.

The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis.

von Meyenfeldt EM, Gooiker GA, van Gijn W, Post PN, van de Velde CJ, Tollenaar RA, Klomp HM, Wouters MW.

J Thorac Oncol. 2012 Jul;7(7):1170-8. doi: 10.1097/JTO.0b013e318257cc45. Review.

24.

Diffuse reflectance spectroscopy: a new guidance tool for improvement of biopsy procedures in lung malignancies.

Evers DJ, Nachabé R, Klomp HM, van Sandick JW, Wouters MW, Lucassen GW, Hendriks BH, Wesseling J, Ruers TJ.

Clin Lung Cancer. 2012 Nov;13(6):424-31. doi: 10.1016/j.cllc.2012.02.001. Epub 2012 Apr 24.

PMID:
22534415
25.

Local treatment of pulmonary metastases: from open resection to minimally invasive approach? Less morbidity, comparable local control.

von Meyenfeldt EM, Wouters MW, Fat NL, Prevoo W, Burgers SA, van Sandick JW, Klomp HM.

Surg Endosc. 2012 Aug;26(8):2312-21. doi: 10.1007/s00464-012-2181-z. Epub 2012 Feb 21.

PMID:
22350235
26.

Concurrent high-dose radiotherapy with low-dose chemotherapy in patients with non-small cell lung cancer of the superior sulcus.

Kappers I, Klomp HM, Koolen MG, Uitterhoeve LJ, Kloek JJ, Belderbos JS, Burgers JA, Koning CC.

Radiother Oncol. 2011 Nov;101(2):278-83. doi: 10.1016/j.radonc.2011.05.030. Epub 2011 Jun 30.

PMID:
21723638
27.

Local progression after radiofrequency ablation for pulmonary metastases.

von Meyenfeldt EM, Prevoo W, Peyrot D, Lai A Fat N, Burgers SJ, Wouters MW, Klomp HM.

Cancer. 2011 Aug 15;117(16):3781-7. doi: 10.1002/cncr.25958. Epub 2011 Feb 11.

28.

Differences in glycemic control and survival predict higher ESRD rates in diabetic First Nations adults.

Dyck RF, Sidhu N, Klomp H, Cascagnette PJ, Teare GF.

Clin Invest Med. 2010 Dec 1;33(6):E390-7.

PMID:
21134341
29.

Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.

Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM, Linn SC.

J Thorac Oncol. 2010 Dec;5(12):1939-48. doi: 10.1097/JTO.0b013e3181f77a39.

30.

Microscopic disease extension in three dimensions for non-small-cell lung cancer: development of a prediction model using pathology-validated positron emission tomography and computed tomography features.

van Loon J, Siedschlag C, Stroom J, Blauwgeers H, van Suylen RJ, Knegjens J, Rossi M, van Baardwijk A, Boersma L, Klomp H, Vogel W, Burgers S, Gilhuijs K.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):448-56. doi: 10.1016/j.ijrobp.2010.09.001. Epub 2010 Oct 23.

PMID:
20971575
31.

Measuring quality of diabetes care by linking health care system administrative databases with laboratory data.

Klomp H, Dyck RF, Sidhu N, Cascagnette PJ, Teare GF.

BMC Res Notes. 2010 Aug 31;3:233. doi: 10.1186/1756-0500-3-233.

32.

Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?

Aukema TS, Kappers I, Olmos RA, Codrington HE, van Tinteren H, van Pel R, Klomp HM; NEL Study Group.

J Nucl Med. 2010 Sep;51(9):1344-8. doi: 10.2967/jnumed.110.076224. Epub 2010 Aug 18.

33.

Taking a closer look: using statistical process control to identify patterns of improvement in a quality-improvement collaborative.

Timmerman T, Verrall T, Clatney L, Klomp H, Teare G.

Qual Saf Health Care. 2010 Dec;19(6):e19. doi: 10.1136/qshc.2008.029025. Epub 2010 Jul 1.

PMID:
20595718
34.

Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, Klomp HM, Abdelrahman AM, Welch J, van Meerbeeck JP; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group.

Eur Respir J. 2010 Dec;36(6):1362-9. doi: 10.1183/09031936.00039510. Epub 2010 Jun 4.

35.

Resection of secondary pulmonary malignancies in head and neck cancer patients.

Geurts TW, Klomp HM, Burgers SA, van Tinteren H, Roukema BY, Balm AJ.

J Laryngol Otol. 2010 Dec;124(12):1278-83. doi: 10.1017/S0022215110001064. Epub 2010 Jun 2.

PMID:
20519045
36.

Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment.

Kappers I, Vollebergh MA, van Tinteren H, Korse CM, Nieuwenhuis LL, Bonfrer JM, Klomp HM, van Zandwijk N, van den Heuvel MM.

Ecancermedicalscience. 2010;4:178. doi: 10.3332/ecancer.2010.178. Epub 2010 Nov 3.

37.

EGFR-TKI treatment and surgical resection for oligometastatic NSCLC?

Klomp HM, Kappers I.

Onkologie. 2009 Nov;32(11):627-8. doi: 10.1159/000246616. Epub 2009 Oct 20. No abstract available.

38.

Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection.

Kappers I, van Sandick JW, Burgers JA, Belderbos JS, Wouters MW, van Zandwijk N, Klomp HM.

Eur J Cardiothorac Surg. 2009 Oct;36(4):741-6. doi: 10.1016/j.ejcts.2009.04.069. Epub 2009 Aug 21.

PMID:
19699647
39.

Evaluation of (18)F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment.

Aukema TS, Valdés Olmos RA, Klomp HM, Teertstra HJ, Belderbos JS, Vogel WV, Baas P, Burgers SA, van den Heuvel MM.

J Thorac Oncol. 2009 Oct;4(10):1226-30. doi: 10.1097/JTO.0b013e3181b2b782.

40.

Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.

Kappers I, van Sandick JW, Burgers SA, Belderbos JS, van Zandwijk N, Klomp HM.

Lung Cancer. 2010 May;68(2):222-7. doi: 10.1016/j.lungcan.2009.07.001. Epub 2009 Aug 6.

PMID:
19664843
41.

The intermediate effect and the diagnostic accuracy in clinical case recall of students and experts in dental medicine.

Eberhard J, Klomp HJ, Föge M, Hedderich J, Schmidt HG.

Eur J Dent Educ. 2009 Aug;13(3):128-34. doi: 10.1111/j.1600-0579.2008.00550.x.

PMID:
19630930
42.

A prognostic model for amputation in critical lower limb ischemia.

Klomp HM, Steyerberg EW, Wittens CH, van Urk H, Habbema JD; ESES study group.

Vasc Med. 2009 May;14(2):109-15. doi: 10.1177/1358863X08098227.

PMID:
19366816
43.

Is pneumonectomy justified in patients with locally advanced NSCLC and persistent N2 disease after induction chemotherapy?

Klomp HM, Kappers I.

Ann Thorac Surg. 2009 Mar;87(3):990-1. doi: 10.1016/j.athoracsur.2008.09.056. No abstract available.

PMID:
19231456
44.

The role of pathophysiological explanations in clinical case representations of dental students and experts.

Klomp HJ, Eberhard J, Hren S, Hedderich J, Schmidt HG.

Eur J Dent Educ. 2009 Feb;13(1):58-65. doi: 10.1111/j.1600-0579.2008.00539.x.

PMID:
19196295
45.

What is the evidence on efficacy of spinal cord stimulation in (subgroups of) patients with critical limb ischemia?

Klomp HM, Steyerberg EW, Habbema JD, van Urk H; ESES study group.

Ann Vasc Surg. 2009 May-Jun;23(3):355-63. doi: 10.1016/j.avsg.2008.08.016. Epub 2009 Jan 6. Review.

PMID:
19128928
46.

Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer.

Geurts TW, Balm AJ, van Velthuysen ML, van Tinteren H, Burgers JA, van Zandwijk N, Klomp HM.

Head Neck. 2009 Feb;31(2):220-6. doi: 10.1002/hed.20952.

PMID:
18972427
47.

Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma.

Tournoy KG, Burgers SA, Annema JT, Vermassen F, Praet M, Smits M, Klomp HM, van Meerbeeck JP, Baas P.

Clin Cancer Res. 2008 Oct 1;14(19):6259-63. doi: 10.1158/1078-0432.CCR-07-5283.

48.

Outcome after surgical resections of recurrent chest wall sarcomas.

Wouters MW, van Geel AN, Nieuwenhuis L, van Tinteren H, Verhoef C, van Coevorden F, Klomp HM.

J Clin Oncol. 2008 Nov 1;26(31):5113-8. doi: 10.1200/JCO.2008.17.4631. Epub 2008 Sep 15.

PMID:
18794540
49.

Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.

Kappers I, Klomp HM, Burgers JA, Van Zandwijk N, Haas RL, van Pel R.

J Clin Oncol. 2008 Sep 1;26(25):4205-7. doi: 10.1200/JCO.2008.16.3709. No abstract available.

PMID:
18757336
50.

Surgical treatment in the management of malignant pleural mesothelioma: a single institution's experience.

van Sandick JW, Kappers I, Baas P, Haas RL, Klomp HM.

Ann Surg Oncol. 2008 Jun;15(6):1757-64. doi: 10.1245/s10434-008-9899-9. Epub 2008 Apr 9.

PMID:
18398658

Supplemental Content

Support Center